Skip to main content
. 2016 Apr;7(2):85–93. doi: 10.1177/2040620715622613

Table 1.

Summary of functional differences between type I and type II mAbs.

Type I mAbs: rituximab, ofatumumab, ublituximab, veltuzumab Type II mAbs: obinutuzumab, tositumomab
Class I epitope Class II epitope

  • Localization of CD20 into lipid rafts

  • High CDC

  • No localization of CD20 into lipid rafts

  • Low CDC

  • No homotypic adhesion

  • Inducing cell death by apoptosis (caspase-dependent)

  • Homotypic adhesion

  • Inducing noncaspase-dependent direct cell death

  • Full CD20 binding capacity at saturating conditions

  • Half-maximal CD20 binding at saturating conditions

  • Stimulating greater levels of apoptotic induction

  • CD20 modulation

  • Less or no CD20 modulation
Induce ADCC
Induce ADCP

ADCC, antibody-dependent cell-mediated cytotoxicity; ADCP, antibody-dependent cellular phagocytosis; CDC, complement-dependent cytotoxicity; mAb, monoclonal antibody.